Novartis' Sandoz to invest $400M to build biosimilar production plant in Slovenia

  • Novartis (NYSE:NVS) said Sandoz will invest at least $400M to build a new biologics production plant in Lendava, Slovenia to support global demand for biosimilar therapies.
  • The Swiss pharma giant’s’ generic and biosimilar unit Sandoz — which is heading for a spin off — signed a Memorandum of Understanding (MOU) at ceremony led by Slovenian Prime Minister Robert Golob and Sandoz CEO  Richard Saynor.
  • Novartis said the project is aimed at boosting Sandoz’s ambition for growing its biosimilars portfolio to meet global demand.
  • According to the company, it will be the one of the largest-ever international private-sector investments in Slovenia.
  • “The location offers us a strong combination of political stability, proximity to our existing European-based production and commercial operations, and competitive costs,” said Glenn Gerecke, global head of Sandoz Technical Operations.
  • Work on the site will begin this year, and full operations are provisionally expected for late 2026.
  • Previously, Sandoz announced an additional €50M investment to expand its European-based antibiotics production network. The company noted that the it brings the total new investment commitment to the network in the past few years to €250M.

Now read: Walgreens, Rite Aid, CVS pressed on access to abortion pill from New York governor, AG

Continue Reading